Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Cost-Effectiveness of an RSVpreF Vaccine for Prevention of Respiratory Syncytial Virus Outcomes in Infants

Details

Files
Project Status:
Complete
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HE0044-000

This review examined the cost-effectiveness of an RSVpreF maternal vaccine administered during pregnancy for the prevention of respiratory syncytial virus outcomes in infants and in people who are pregnant.

Files

Cost-Effectiveness of an RSVpreF Vaccine for Prevention of Respiratory Syncytia… View PDF
Last Updated : August 8, 2023